The pharmacovigilance and drug safety software market in North America is expected to grow from US$73.4 million in 2019 to US$136.0 million in 2027; It is estimated to grow at a CAGR of 7.8% from 2020 to 2027.

The report entitled “Pharmacovigilance and Drug Safety Software Market in North America 2022-2027” was recently added by Business Market Insights to create a stronger and more effective business outlook. It offers an in-depth analysis of the various attributes of the industry, such as trends, policies, and clients operating in multiple regions. Research analysts use both quantitative and qualitative analysis techniques to provide users, business owners, and industry professionals with accurate and actionable data. The North America Pharmacovigilance and Drug Safety Software Market study provides comprehensive data that enhances the understanding, scope and application during the forecast period 2022-2027.

Get a sample copy of the report, click here: https://www.businessmarketinsights.com/sample/TIPRE00022774

The major players in this market are:

  • Veeva systems
  • IQVIA Inc.
  • Ennov
  • AB cube
  • United Biosource LLC
  • Aris Global LLC
  • Sparta systems
  • Oracle Corporation
  • Sarjen Systems Pvt. GmbH
  • EXTEDO
  • Online Business Applications, Inc.

North America Pharmacovigilance and Drug Safety Software Market Segmentation:

By software type

  • Fully integrated software
  • Adverse event reporting software
  • Drug safety audit software
  • Issue tracking software

By delivery mode

By end users

  • contract research organizations
  • pharmaceutical and biotech companies
  • Business process outsourcing

By country

  • North America
  • US
  • Canada
  • Mexico

Analysis of the top market players:

Competition can be an important issue in any market research analysis. This is a report compiled with the help of competitive analysis, provided players can simply study the key strategies adopted by leading players in the North America Pharmacovigilance and Drug Safety Software market up to 2027. Important and emerging…

[ad_2]

Source story